Topoisomerase II Poisoning and DAMP Egress Signatures
Doxorubicin acts as an anthracycline chemotherapeutic that intercalates between adjacent DNA base pairs and traps topoisomerase II in covalent cleavage complexes [1]. This molecular trapping arrests replication forks and yields toxic double-strand breaks characterized by rapid γ-H2AX phosphorylation within 2 to 6 hours post-treatment [1][2]. In RKO colon carcinoma cells, exposure to doxorubicin triggers robust apoptotic cascades mediated by caspase-3-dependent poly(ADP-ribose) polymerase (PARP) cleavage [3]. Beyond genotoxic cytotoxicity, topoisomerase II inhibition induces endoplasmic reticulum (ER) stress, driving protein kinase RNA-like endoplasmic reticulum kinase (PERK) activation and subsequent phosphorylation of eukaryotic initiation factor 2α (eIF2α) [1][3].
This ER stress cascade orchestrates the anterograde vesicular transport and pre-apoptotic externalization of calreticulin (CRT) to the outer leaflet of the plasma membrane [1][3]. Simultaneously, cellular ATP pools undergo active extracellular secretion through pannexin-1 hemichannels, while high-mobility group box 1 (HMGB1) disengages from chromatin and traverses permeable membranes into the tumor microenvironment [1][2]. Studies utilizing the S1601 lung adenocarcinoma model demonstrate that short-pulse doxorubicin treatment (6 hours) elicits substantial nanometer-scale extracellular ATP release and promotes marked CRT surface redistribution, establishing a bona fide immunogenic cell death (ICD) phenotype [2].
These coordinated danger-associated molecular patterns (DAMPs) serve as critical signals for dendritic cell (DC) recruitment and engulfment [1][3]. As detailed in Table 1, the pharmacodynamic parameters governing doxorubicin-mediated ICD show distinct cellular thresholds relative to non-immunogenic cytotoxic benchmarks. While doxorubicin successfully triggers CRT display and DAMP release across diverse malignancies, physiological immunosuppression and physical cytoskeletal barriers in the tumor stroma frequently curtail effective antigen processing in vivo, highlighting the requirement for targeted adjunct interventions [3][4].
Rho-Associated Kinase Suppression in Dendritic Cell Cytodynamics
The small GTPase RhoA and its downstream effector Rho-associated coiled-coil containing protein kinase (ROCK) regulate the assembly of stress fibers and cortical actomyosin contractility in myeloid lineages [4]. Y-27632 functions as a competitive ATP-binding site inhibitor selective for ROCK1 (Ki 140 nM) and ROCK2 (Ki 220 nM), displaying more than 20-fold selectivity over protein kinase C and protein kinase B [4]. Under homeostatic conditions or in response to tumor-derived mechanical compression, elevated ROCK signaling promotes the phosphorylation of LIM kinase and myosin light chain (MLC) on Thr18 and Ser19, enforcing a rigid subcortical actin meshwork that limits membrane deformability [4].
In preclinical investigations using B16-F10 melanoma xenografts, monotherapy with doxorubicin exhibits limited curative immunogenicity in vivo due to defective phagocytic uptake of dying cell fragments by antigen-presenting cells [4][5]. Pharmacological disruption of ROCK via Y-27632 reduces phospho-MLC levels, disassembling cortical F-actin bundles and decreasing membrane cortical tension in dendritic cells [4]. This biomechanical softening significantly increases fluid-phase macropinocytosis and accelerates the direct phagocytic engulfment of doxorubicin-injured tumor corpses [4].
Concurrently, ROCK blockade influences DC cytodynamics within secondary lymphoid organs [4]. Although systemic RhoA/ROCK disruption can diminish generalized cell crawling velocity in single-cell in vitro matrices, in vivo models demonstrate that Y-27632 administration increases the frequency of migratory CD103+ conventional dendritic cells (cDCs) within tumor-draining lymph nodes [4]. This migratory influx is supported by CLEC-2-dependent crawling along fibroblastic reticular cell conduits, which is favored when cortical actomyosin hyper-contractility is relieved [4]. Consequently, targeting ROCK relieves mechanical constraints, permitting unhindered DC mobilization toward tumor antigens.
Synergistic Upregulation of Co-Stimulatory Receptors CD40 and CD86
Phagocytosis of doxorubicin-killed tumor fragments delivers concentrated cargo of HMGB1 and extracellular ATP to pattern recognition receptors on immature dendritic cells [1][4]. Binding of HMGB1 to Toll-like receptor 4 (TLR4) recruits the myeloid differentiation primary response 88 (MyD88) adapter complex, initiating degradation of IκBα and driving nuclear translocation of NF-κB heterodimers (p50/p65) [1][6]. Coincidentally, purinergic P2X7 receptor ligation by extracellular ATP triggers the NLRP3 inflammasome, accelerating active caspase-1 cleavage and driving interleukin-1β (IL-1β) secretion [1].
Combining doxorubicin-induced ICD with Y-27632-mediated ROCK inhibition generates marked synergy in DC maturation signatures [4]. Pharmacological ROCK inhibition amplifies TLR-induced receptor trafficking toward the cell surface by destabilizing cortical actin networks that otherwise impede exocytic vesicle fusion [4]. Multiparameter flow cytometry demonstrates that while doxorubicin or Y-27632 monotherapy produces minor shifts in maturation markers, dual treatment yields an increase exceeding 3.5-fold in median fluorescence intensity for CD86 and CD40 on CD11c+ cDCs [4].
This receptor upregulation is accompanied by an enhanced capacity of cDCs to prime naive T cells [4]. Classical cytotoxic chemotherapy often provokes counter-regulatory immunosuppression via negative feedback mechanisms such as programmed death-ligand 1 (PD-L1) induction [6]. However, combined doxorubicin and Y-27632 regimens preserve high ratios of co-stimulatory molecules (CD80, CD86, CD40) relative to inhibitory checkpoint ligands [4][6]. Elevated CD40 expression licenses dendritic cells by stimulating endogenous interleukin-12 (IL-12) transcription, establishing a persistent state of functional competence required for antigen presentation [4].
Antigenic Processing Mechanics and MHC-I Neoepitope Cross-Presentation
Cross-presentation requires that exogenous phagocytosed tumor neoantigens evade complete lysosomal destruction and access cytosolic degradation complexes [4][6]. In typical endocytic routes, rapid lysosomal fusion and excessive phagosomal acidification can proteolytically destroy antigenic determinants before MHC-I loading occurs [4]. ROCK inhibition moderates phagosome-lysosome fusion rates and controls local NADPH oxidase 2 (NOX2) assembly, thereby preventing excessive phagolysosomal hyper-acidification [4].
Following controlled early-endosomal processing, intact polypeptides are translocated into the cytosol, where they undergo cleavage by the 20S/26S core proteasome machinery [4][6]. Concurrently, cytosolic release of damaged mitochondrial DNA (mtDNA) and nuclear DNA fragments triggered by doxorubicin activates the cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) axis [6]. STING activation promotes tank-binding kinase 1 (TBK1) phosphorylation and interferon regulatory factor 3 (IRF3) nuclear translocation, resulting in sustained transcription of type I interferons (IFN-α/β) [6].
Type I interferons stimulate the peptide-loading complex, markedly elevating expression of the transporter associated with antigen processing 1 and 2 (TAP1/TAP2), tapasin, and calnexin [4][6]. Processed antigenic peptides are actively pumped into the ER lumen, trimmed by endoplasmic reticulum aminopeptidase 1 (ERAP1), and assembled into stable heterotrimers with β2-microglobulin and MHC class I heavy chains [4][6]. In syngeneic models expressing ovalbumin, tracking via the 25-D1.16 monoclonal antibody confirms elevated cell-surface density of SIINFEKL-H-2Kb complexes following combined doxorubicin and Y-27632 treatment [4]. This confirms that combined topoisomerase II poisoning and ROCK inhibition coordinates both antigen preservation and efficient surface cross-presentation.
Cytotoxic CD8+ T Cell Priming and Effector Readouts
Robust surface display of MHC-I-neoepitope complexes, alongside enriched CD40 and CD86 engagement, lowers the energetic threshold for T-cell receptor (TCR) signal transduction in naive antigen-specific CD8+ T cells [4][7]. Co-culture of OT-I CD8+ T cells with cDCs primed by the combination regimen induces rapid clonal expansion, documented by progressive carboxyfluorescein succinimidyl ester (CFSE) dilution over 72 hours [4]. In contrast, DCs exposed to doxorubicin monotherapy drive modest T cell cycle entry, underscoring the indispensable adjuvant role of ROCK suppression [4].
Functional profiling demonstrates potent cytotoxic polarization [7]. Intracellular flow cytometric staining reveals significant elevations in the proportion of tumor-infiltrating CD8+ T cells expressing interferon-gamma (IFN-γ), granzyme B, and perforin-1 following doxorubicin administration [7]. In murine tumor models, doxorubicin exposure increases the frequency of IFN-γ+ CD8+ T cells (87.5% versus 74.4% in controls), granzyme B+ CD8+ T cells (86.5% versus 68.9%), and perforin+ CD8+ T cells (50.5% versus 22.2%) [7]. These effector cells execute direct target cell lysis upon antigen re-encounter without rapid induction of exhaustion markers such as TIM-3 or LAG-3 [7].
Furthermore, the therapeutic combination alters the intra-tumoral immune composition by reducing Foxp3+ CD4+ regulatory T cells (Tregs) and expanding CD103+ tissue-resident memory T cells (TRM) [7]. Tregs diminish from 40.2% in control cohorts to 13.6% in doxorubicin-treated arms, effectively removing potent local immunosuppression [7]. Concurrently, CD103+ TRM cell infiltration increases from 2.24% to 6.43%, establishing persistent immune surveillance within the tumor niche [7]. When re-challenged with parental tumor cell lines in syngeneic vaccination assays, animals receiving combinations of bona fide ICD inducers and cytoskeletal modulators demonstrate complete protection against secondary tumor engraftment, confirming the induction of systemic, durable antineoplastic immunity [4][5].